St. Jude Medical’s Axium chronic pain device makes its U.S. debut

St. Jude Medical (NYSE:STJ) today announced the U.S. debut of its Axium neurostimulator system, after the device won FDA approval in February for treating chronic pain. The 1st patients were implanted in West Virginia and California with the Axium device, which uses dorsal root ganglion stimulation to treat moderate to severe chronic intractable pain of the lower limbs in adult patients with complex regional pain syndrome, St. Jude said. The Axium is slated to be implanted in 25 states in the coming weeks, with 100 procedures due in the 1st month after launch, the Little Canada, Minn.-based company said. “Since the approval of dorsal root ganglion stimulation with the Axium system in February 2016, we have focused on a strategic rollout with a disciplined training program for physicians across the country. We believe this approach ensures patient access to this highly effective new therapy to help manage their chronic pain,” vice president Dr. Allen Burton said in prepared remarks. “The 1st Axium system implants in the United States reflect our ongoing commitment to working with our physician partners to deliver on our promise to transform the treatment of chronic pain.” St. Jude said it aims to train more than 300 surgeons on implanting the Axium device this year. “Although many chronic pain patients can find relief from a traditional spinal cord stimulation device, many patients suffering from focal chronic pain including CRPS I ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Neuromodulation/Neurostimulation Pain Management Wall Street Beat St. Jude Medical Source Type: news